REGN7075 (Not yet branded)

Other Medications

US Experimental IV 3 Clinical Trials
Undisclosed immune checkpoint target

Description

REGN7075 is an experimental immunotherapy agent being evaluated in combination with cemiplimab and other therapies for the treatment of microsatellite stable (MSS) colorectal cancer. This compound is specifically being tested in locally advanced rectal cancer patients as part of combination regimens that include standard chemotherapy with capecitabine and oxaliplatin. REGN7075 represents part of Regeneron's pipeline of novel immune checkpoint modulators designed to enhance anti-tumor immune responses in cancers that typically do not respond well to conventional immunotherapy.

Mechanism of Action

Based on its development context and combination with cemiplimab (anti-PD-1), REGN7075 likely targets a complementary immune checkpoint pathway to enhance T-cell activation and overcome immune suppression in the tumor microenvironment. The precise molecular target has not been publicly disclosed, but it appears designed to work synergistically with PD-1 inhibition to improve immune recognition and destruction of cancer cells in MSS colorectal tumors.

Molecular Targets

Side Effects

Specific side effect profile not yet established Likely immune-related adverse events similar to other checkpoint inhibitors Fatigue Skin reactions Gastrointestinal effects Potential autoimmune complications

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT07281768 Phase 2
Recruiting
Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer
United States
NCT07058012 Phase 2
Recruiting
A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)
United States
NCT04626635 Phase 1
Active, not recruiting
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
United States, France, Israel, Netherlands, Poland, Spain, Turkey (Türkiye)

Quick Info

Brand NameNot yet branded
CategoryOther Medications
US StatusExperimental
AdministrationIV
Clinical Trials3
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
785 trials
Leucovorin
Other Medications
646 trials
Paclitaxel
Other Medications
54 trials
Trifluridine
Other Medications
50 trials
Cyclophosphamid
Other Medications
50 trials
Cyclophosphamide
Other Medications
49 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.